{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:15:33Z","timestamp":1777392933975,"version":"3.51.4"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007211","name":"Vasculitis Foundation","doi-asserted-by":"publisher","award":["N&A"],"award-info":[{"award-number":["N&A"]}],"id":[{"id":"10.13039\/100007211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004004","name":"Universit\u00e0 degli Studi di Trento","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004004","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40266-025-01210-8","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:26:23Z","timestamp":1748683583000},"page":"615-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aging in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: From Pathophysiology to Clinical Management"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9646-7603","authenticated-orcid":false,"given":"Baptiste","family":"Chevet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9272-1703","authenticated-orcid":false,"given":"Giulia","family":"Boscato Sopetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-9549","authenticated-orcid":false,"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-1206","authenticated-orcid":false,"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-921X","authenticated-orcid":false,"given":"Alvise","family":"Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-702X","authenticated-orcid":false,"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"1210_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2020.104034","volume":"49","author":"L Guillevin","year":"2020","unstructured":"Guillevin L. Treatment of systemic necrotizing vasculitides: the 40-year experience of the French Vasculitis Study Group. Presse Med. 2020;49: 104034.","journal-title":"Presse Med"},{"key":"1210_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1210_CR3","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","volume":"30","author":"RA Watts","year":"2015","unstructured":"Watts RA, et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14-22.","journal-title":"Nephrol Dial Transplant"},{"key":"1210_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599\u2013609.","journal-title":"N Engl J Med"},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.berh.2018.09.001","volume":"32","author":"A Berti","year":"2018","unstructured":"Berti A, Dejaco C. Update on the epidemiology, risk factors, and outcomes of systemic vasculitides. Best Pract Res Clin Rheumatol. 2018;32:271\u201394.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in olmsted county, minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 2017;69:2338\u201350.","journal-title":"Arthritis Rheumatol"},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"iii42","DOI":"10.1093\/rheumatology\/keaa089","volume":"59","author":"AJ Mohammad","year":"2020","unstructured":"Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59:iii42\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR8","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.3390\/jcm11092573","volume":"11","author":"R Redondo-Rodriguez","year":"2022","unstructured":"Redondo-Rodriguez R, et al. Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. J Clin Med. 2022;11:2573.","journal-title":"J Clin Med"},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/rheumatology\/keaa699","volume":"60","author":"J Rathmann","year":"2021","unstructured":"Rathmann J, Jayne D, Segelmark M, J\u00f6nsson G, Mohammad AJ. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatology (Oxford). 2021;60:2745\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102910","volume":"133","author":"PM Bataille","year":"2022","unstructured":"Bataille PM, et al. Epidemiology of granulomatosis with polyangiitis and microscopic polyangiitis in adults in France. J Autoimmun. 2022;133: 102910.","journal-title":"J Autoimmun"},{"key":"1210_CR11","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/rheumatology\/kew232","volume":"55","author":"FA Pearce","year":"2016","unstructured":"Pearce FA, et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology (Oxford). 2016;55:1656\u201363.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tem.2016.09.005","volume":"28","author":"C Franceschi","year":"2017","unstructured":"Franceschi C, Garagnani P, Vitale G, Capri M, Salvioli S. Inflammaging and \u2018Garb-aging.\u2019 Trends Endocrinol Metab. 2017;28:199\u2013212.","journal-title":"Trends Endocrinol Metab"},{"key":"1210_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194\u2013217.","journal-title":"Cell"},{"key":"1210_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis V, et al. Cellular senescence: defining a path forward. Cell. 2019;179:813\u201327.","journal-title":"Cell"},{"key":"1210_CR15","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.4049\/jimmunol.0901022","volume":"184","author":"A Panda","year":"2010","unstructured":"Panda A, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184:2518\u201327.","journal-title":"J Immunol"},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cellimm.2004.07.001","volume":"229","author":"J Plowden","year":"2004","unstructured":"Plowden J, et al. Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function. Cell Immunol. 2004;229:86\u201392.","journal-title":"Cell Immunol"},{"key":"1210_CR17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.4049\/jimmunol.178.2.970","volume":"178","author":"D van Duin","year":"2007","unstructured":"van Duin D, et al. Age-associated defect in human TLR-1\/2 function. J Immunol. 2007;178:970\u20135.","journal-title":"J Immunol"},{"key":"1210_CR18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4049\/jimmunol.1700148","volume":"199","author":"TU Metcalf","year":"2017","unstructured":"Metcalf TU, et al. Human monocyte subsets are transcriptionally and functionally altered in aging in response to pattern recognition receptor agonists. J Immunol. 2017;199:1405\u201317.","journal-title":"J Immunol"},{"key":"1210_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005368","volume":"12","author":"A Puchta","year":"2016","unstructured":"Puchta A, et al. TNF drives monocyte dysfunction with age and results in impaired anti-pneumococcal immunity. PLoS Pathog. 2016;12: e1005368.","journal-title":"PLoS Pathog"},{"key":"1210_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.exger.2014.01.008","volume":"54","author":"C Campos","year":"2014","unstructured":"Campos C, et al. Effect of age and CMV on NK cell subpopulations. Exp Gerontol. 2014;54:130\u20137.","journal-title":"Exp Gerontol"},{"key":"1210_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10522-014-9514-3","volume":"16","author":"J Hazeldine","year":"2015","unstructured":"Hazeldine J, Lord JM. Innate immunesenescence: underlying mechanisms and clinical relevance. Biogerontology. 2015;16:187\u2013201.","journal-title":"Biogerontology"},{"key":"1210_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1189\/jlb.5MR0315-104R","volume":"98","author":"RR Montgomery","year":"2015","unstructured":"Montgomery RR, Shaw AC. Paradoxical changes in innate immunity in aging: recent progress and new directions. J Leukoc Biol. 2015;98:937\u201343.","journal-title":"J Leukoc Biol"},{"key":"1210_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02664","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa M, et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.02664.","journal-title":"Front Immunol"},{"key":"1210_CR24","doi-asserted-by":"publisher","first-page":"8689","DOI":"10.3390\/ijms23158689","volume":"23","author":"R Zheng","year":"2022","unstructured":"Zheng R, et al. The complement system, aging, and aging-related diseases. Int J Mol Sci. 2022;23:8689.","journal-title":"Int J Mol Sci"},{"key":"1210_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926044","author":"Y Kimoto","year":"2022","unstructured":"Kimoto Y, Horiuchi T. The complement system and ANCA associated vasculitis in the era of anti-complement drugs. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.926044.","journal-title":"Front Immunol"},{"key":"1210_CR26","unstructured":"Merkel PA, Pfaff A, M\u00fcller C, Startseva E & Jayne DR. A randomized, double-blind, phase II study of glucocorticoid replacement by vilobelimab, an anti-C5a monoclonal antibody, in ANCA-associated vasculitis. ACR Meeting Abstracts (2022)."},{"key":"1210_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev-cellbio-011620-034148","volume":"36","author":"D Frasca","year":"2020","unstructured":"Frasca D, Diaz A, Romero M, Garcia D, Blomberg BB. B Cell Immunosenescence. Annu Rev Cell Dev Biol. 2020;36:551\u201374.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1210_CR28","doi-asserted-by":"publisher","unstructured":"Naylor K, Li G, Vallejo AN, et al. The influence of age on T cell generation and TCR diversity. J Immunol. 2005;174(11):7446\u201352. https:\/\/doi.org\/10.4049\/jimmunol.174.11.7446.","DOI":"10.4049\/jimmunol.174.11.7446"},{"key":"1210_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","volume":"120","author":"D Aw","year":"2007","unstructured":"Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435\u201346.","journal-title":"Immunology"},{"key":"1210_CR30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/ni.3483","volume":"17","author":"V Pulko","year":"2016","unstructured":"Pulko V, et al. Human memory T cells with a naive phenotype accumulate with aging and respond to persistent viruses. Nat Immunol. 2016;17:966\u201375.","journal-title":"Nat Immunol"},{"key":"1210_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2020.110887","volume":"134","author":"L Pangrazzi","year":"2020","unstructured":"Pangrazzi L, Weinberger B. T cells, aging and senescence. Exp Gerontol. 2020;134: 110887.","journal-title":"Exp Gerontol"},{"key":"1210_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.0105-2896.2005.00256.x","volume":"205","author":"AN Vallejo","year":"2005","unstructured":"Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev. 2005;205:158\u201369.","journal-title":"Immunol Rev"},{"key":"1210_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/08830185.2021.1929954","volume":"41","author":"R Song","year":"2022","unstructured":"Song R, Jia X, Zhao J, Du P, Zhang J-A. T cell receptor revision and immune repertoire changes in autoimmune diseases. Int Rev Immunol. 2022;41:517\u201333.","journal-title":"Int Rev Immunol"},{"key":"1210_CR34","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/art.23557","volume":"58","author":"WH Abdulahad","year":"2008","unstructured":"Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CGM. Skewed distribution of Th17 lymphocytes in patients with Wegener\u2019s granulomatosis in remission. Arthritis Rheum. 2008;58:2196\u2013205.","journal-title":"Arthritis Rheum"},{"key":"1210_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00262300","volume":"14","author":"M Schlesier","year":"1995","unstructured":"Schlesier M, Kaspar T, Gutfleisch J, Wolff-Vorbeck G, Peter HH. Activated CD4+ and CD8+ T-cell subsets in Wegener\u2019s granulomatosis. Rheumatol Int. 1995;14:213\u20139.","journal-title":"Rheumatol Int"},{"key":"1210_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1046\/j.1365-2249.1998.00695.x","volume":"114","author":"F Moosig","year":"1998","unstructured":"Moosig F, Csernok E, Wang G, Gross WL. Costimulatory molecules in Wegener\u2019s granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7\u20131 (CD80) and B7\u20132 (CD86) on T cells. Clin Exp Immunol. 1998;114:113\u20138.","journal-title":"Clin Exp Immunol"},{"key":"1210_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/thorax.56.10.751","volume":"56","author":"P Lamprecht","year":"2001","unstructured":"Lamprecht P, et al. CD28 negative T cells are enriched in granulomatous lesions of the respiratory tract in Wegener\u2019s granulomatosis. Thorax. 2001;56:751\u20137.","journal-title":"Thorax"},{"key":"1210_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.smim.2012.04.004","volume":"24","author":"I Kogut","year":"2012","unstructured":"Kogut I, Scholz JL, Cancro MP, Cambier JC. B cell maintenance and function in aging. Semin Immunol. 2012;24:342\u20139.","journal-title":"Semin Immunol"},{"key":"1210_CR39","doi-asserted-by":"crossref","unstructured":"Re Y, Ce G, Cm W & Jj G. Lymphocyte generation and population homeostasis throughout life. Seminars Hematol. 2017;54.","DOI":"10.1053\/j.seminhematol.2016.10.003"},{"key":"1210_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/blood.V91.1.75","volume":"91","author":"RP Stephan","year":"1998","unstructured":"Stephan RP, Reilly CR, Witte PL. Impaired ability of bone marrow stromal cells to support B-lymphopoiesis with age. Blood. 1998;91:75\u201388.","journal-title":"Blood"},{"key":"1210_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.it.2009.03.010","volume":"30","author":"H Geiger","year":"2009","unstructured":"Geiger H, Rudolph KL. Aging in the lympho-hematopoietic stem cell compartment. Trends Immunol. 2009;30:360\u20135.","journal-title":"Trends Immunol"},{"key":"1210_CR42","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jaci.2015.09.014","volume":"137","author":"Q Simon","year":"2016","unstructured":"Simon Q, et al. In-depth characterization of CD24(high)CD38(high) transitional human B cells reveals different regulatory profiles. J Allergy Clin Immunol. 2016;137:1577\u201384 (e10).","journal-title":"J Allergy Clin Immunol"},{"key":"1210_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150999","volume":"6","author":"A Berti","year":"2021","unstructured":"Berti A, et al. Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight. 2021;6: e150999.","journal-title":"JCI Insight"},{"key":"1210_CR44","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/ard-2024-225587","volume":"83","author":"J Thiel","year":"2024","unstructured":"Thiel J, et al. Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis. Ann Rheum Dis. 2024;83:1536\u201348.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR45","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.4049\/jimmunol.172.4.2155","volume":"172","author":"D Frasca","year":"2004","unstructured":"Frasca D, Van der Put E, Riley RL, Blomberg BB. Reduced Ig Class switch in aged mice correlates with decreased E47 and activation-induced cytidine deaminase1. J Immunol. 2004;172:2155\u201362.","journal-title":"J Immunol"},{"key":"1210_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1474-9726.2008.00443.x","volume":"8","author":"KL Gibson","year":"2009","unstructured":"Gibson KL, et al. B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009;8:18\u201325.","journal-title":"Aging Cell"},{"key":"1210_CR47","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","volume":"134","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573\u201389.","journal-title":"Br J Haematol"},{"key":"1210_CR48","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/art.42388","volume":"75","author":"A Berti","year":"2023","unstructured":"Berti A, et al. Autoreactive plasmablasts after B cell depletion with rituximab and relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2023;75:736\u201347.","journal-title":"Arthritis Rheumatol"},{"key":"1210_CR49","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2011-01-330530","volume":"118","author":"Y Hao","year":"2011","unstructured":"Hao Y, O\u2019Neill P, Naradikian MS, Scholz JL, Cancro MP. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. Blood. 2011;118:1294\u2013304.","journal-title":"Blood"},{"key":"1210_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1182\/blood-2011-01-331462","volume":"118","author":"AV Rubtsov","year":"2011","unstructured":"Rubtsov AV, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. Blood. 2011;118:1305\u201315.","journal-title":"Blood"},{"key":"1210_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/acel.12055","volume":"12","author":"M Ratliff","year":"2013","unstructured":"Ratliff M, Alter S, Frasca D, Blomberg BB, Riley RL. In senescence, age-associated B cells secrete TNF\u03b1 and inhibit survival of B-cell precursors. Aging Cell. 2013;12:303\u201311.","journal-title":"Aging Cell"},{"key":"1210_CR52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/rheumatology\/kev293","volume":"55","author":"N Lepse","year":"2016","unstructured":"Lepse N, et al. Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. Rheumatology (Oxford). 2016;55:162\u201372.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac623","author":"B Chevet","year":"2022","unstructured":"Chevet B, et al. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology (Oxford). 2022. https:\/\/doi.org\/10.1093\/rheumatology\/keac623.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/RHU.0b013e31816b2fbd","volume":"14","author":"DD Hoganson","year":"2008","unstructured":"Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly. J Clin Rheumatol. 2008;14:78\u201381.","journal-title":"J Clin Rheumatol"},{"key":"1210_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.23876\/j.krcp.21.008","volume":"41","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Han M, Song SH, Seong EY. Clinical features and outcomes of elderly patients with antineutrophil cytoplasmic antibody-positive vasculitis: a single-center retrospective study. Kidney Res Clin Pract. 2022;41:209\u201318.","journal-title":"Kidney Res Clin Pract"},{"key":"1210_CR56","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","volume":"391","author":"DH Kim","year":"2024","unstructured":"Kim DH, Rockwood K. Frailty in older adults. N Engl J Med. 2024;391:538\u201348.","journal-title":"N Engl J Med"},{"key":"1210_CR57","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s43587-021-00099-3","volume":"1","author":"SE Howlett","year":"2021","unstructured":"Howlett SE, Rutenberg AD, Rockwood K. The degree of frailty as a translational measure of health in aging. Nat Aging. 2021;1:651\u201365.","journal-title":"Nat Aging"},{"key":"1210_CR58","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1100\/tsw.2001.58","volume":"1","author":"AB Mitnitski","year":"2001","unstructured":"Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323\u201336.","journal-title":"ScientificWorldJournal"},{"key":"1210_CR59","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-156.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1210_CR60","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/gerona\/gly110","volume":"74","author":"DL Vetrano","year":"2019","unstructured":"Vetrano DL, et al. Frailty and multimorbidity: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2019;74:659\u201366.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1210_CR61","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2468-2667(18)30091-4","volume":"3","author":"P Hanlon","year":"2018","unstructured":"Hanlon P, et al. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018;3:e323\u201332.","journal-title":"Lancet Public Health"},{"key":"1210_CR62","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","volume":"59","author":"D McGovern","year":"2020","unstructured":"McGovern D, et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59:1076\u201383.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac078","volume":"6","author":"CY Wang","year":"2022","unstructured":"Wang CY, et al. Frailty assessment in ANCA-associated vasculitis: current evidence and remaining uncertainties. Rheumatol Adv Pract. 2022;6: rkac078.","journal-title":"Rheumatol Adv Pract"},{"key":"1210_CR64","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux C, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67:1117\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"1210_CR65","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1378\/chest.109.2.430","volume":"109","author":"SS Krafcik","year":"1996","unstructured":"Krafcik SS, Covin RB, Lynch JP, Sitrin RG. Wegener\u2019s granulomatosis in the elderly. Chest. 1996;109:430\u20137.","journal-title":"Chest"},{"key":"1210_CR66","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/MD.0b013e31817c744b","volume":"87","author":"M Chen","year":"2008","unstructured":"Chen M, Yu F, Zhang Y, Zhao M-H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore). 2008;87:203\u20139.","journal-title":"Medicine (Baltimore)"},{"key":"1210_CR67","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s11255-021-02786-x","volume":"53","author":"T Meng","year":"2021","unstructured":"Meng T, et al. Clinical features and outcomes of anti-neutrophil cytoplasmic autoantibody-associated vasculitis in Chinese elderly and very elderly patients. Int Urol Nephrol. 2021;53:1875\u201381.","journal-title":"Int Urol Nephrol"},{"key":"1210_CR68","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/art.42651","volume":"75","author":"JL Bloom","year":"2023","unstructured":"Bloom JL, et al. The association between age at diagnosis and disease characteristics and damage in patients with ANCA-associated vasculitis. Arthritis Rheumatol. 2023;75:2216\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"1210_CR69","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s11255-014-0717-y","volume":"46","author":"\u00c1 Haris","year":"2014","unstructured":"Haris \u00c1, et al. Clinical outcomes of ANCA-associated vasculitis in elderly patients. Int Urol Nephrol. 2014;46:1595\u2013600.","journal-title":"Int Urol Nephrol"},{"key":"1210_CR70","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.semarthrit.2020.02.008","volume":"50","author":"A Berti","year":"2020","unstructured":"Berti A, et al. Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis. Semin Arthritis Rheum. 2020;50:1441\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"1210_CR71","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2215\/CJN.00990209","volume":"4","author":"D-A Moutzouris","year":"2009","unstructured":"Moutzouris D-A, et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol. 2009;4:1073\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1210_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00193-0","author":"E Sattui","year":"2024","unstructured":"Sattui E, Sebastian E, et al. The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective cohort study. Lancet Rheumatol. 2024. https:\/\/doi.org\/10.1016\/S2665-9913(24)00193-0.","journal-title":"Lancet Rheumatol"},{"key":"1210_CR73","unstructured":"Sattui, S. E. et al. Prevalence of frailty and associated factors in patients with vasculitis. ACR Meeting Abstracts (2022)."},{"key":"1210_CR74","unstructured":"Cipriano J. The impact of age and frailty on outcome risks in older adults with AAV. Rare Disease Advisor. 2023. https:\/\/www.rarediseaseadvisor.com\/reports\/impact-age-frailty-outcome-risks-older-adults-aav\/"},{"key":"1210_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","author":"B Hellmich","year":"2023","unstructured":"Hellmich B, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR76","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827\u201332.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR77","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith RM, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79:1243\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR78","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","volume":"75","author":"S Unizony","year":"2016","unstructured":"Unizony S, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75:1166\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR79","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.24634","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Care Res. 2021;73:1088\u2013105.","journal-title":"Arthritis Care Res"},{"key":"1210_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex459","author":"F Buttgereit","year":"2018","unstructured":"Buttgereit F, Matteson EL, Dejaco C, Dasgupta B. Prevention of glucocorticoid morbidity in giant cell arteritis. Rheumatology. 2018. https:\/\/doi.org\/10.1093\/rheumatology\/kex459.","journal-title":"Rheumatology"},{"key":"1210_CR81","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/acr.21812","volume":"65","author":"J Widdifield","year":"2013","unstructured":"Widdifield J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:353\u201361.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1210_CR82","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","volume":"30","author":"L Fardet","year":"2007","unstructured":"Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf. 2007;30:861\u201381.","journal-title":"Drug Saf"},{"key":"1210_CR83","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13075-020-02341-6","volume":"22","author":"K-E Sada","year":"2020","unstructured":"Sada K-E, et al. Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies. Arthritis Res Ther. 2020;22:236.","journal-title":"Arthritis Res Ther"},{"key":"1210_CR84","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000506532","volume":"51","author":"AD Morris","year":"2020","unstructured":"Morris AD, et al. Treatment outcomes of anti-neutrophil cytoplasmic autoantibody-associated vasculitis in patients over age 75 years: a meta-analysis. Am J Nephrol. 2020;51:327\u201336.","journal-title":"Am J Nephrol"},{"key":"1210_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"1210_CR86","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105, S71\u2013116.","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"1210_CR87","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.20925","volume":"5","author":"S Thietart","year":"2022","unstructured":"Thietart S, et al. Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody\u2013associated vasculitis. JAMA Netw Open. 2022;5: e2220925.","journal-title":"JAMA Netw Open"},{"key":"1210_CR88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semarthrit.2015.02.005","volume":"45","author":"H Timlin","year":"2015","unstructured":"Timlin H, Lee SM, Manno RL, Seo P, Geetha D. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum. 2015;45:67\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"1210_CR89","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/ki.2010.489","volume":"79","author":"AS Bomback","year":"2011","unstructured":"Bomback AS, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757\u201364.","journal-title":"Kidney Int"},{"key":"1210_CR90","doi-asserted-by":"crossref","unstructured":"Jayne DR, Geetha D, Pagnoux C, Sattui SE & Merkel PA. Safety and efficacy of avacopan in patients 65 years and older with ANCA-associated vasculitis. ACR Meeting Abstracts. https:\/\/acrabstracts.org\/abstract\/safety-and-efficacy-of-avacopan-in-patients-65-years-and-older-with-anca-associated-vasculitis\/ (2023).","DOI":"10.1681\/ASN.20233411S1969b"},{"key":"1210_CR91","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/mr\/roac037","volume":"33","author":"M Harigai","year":"2023","unstructured":"Harigai M, et al. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: a subanalysis of a randomized Phase 3 study. Mod Rheumatol. 2023;33:338\u201345.","journal-title":"Mod Rheumatol"},{"key":"1210_CR92","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380.","journal-title":"N Engl J Med"},{"key":"1210_CR93","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173:179\u201387.","journal-title":"Ann Intern Med"},{"key":"1210_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224623","author":"F Delestre","year":"2023","unstructured":"Delestre F, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2023-224623.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR95","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/acr.24332","volume":"73","author":"PA Merkel","year":"2021","unstructured":"Merkel PA, et al. Long-term safety of rituximab in granulomatosis with polyangiitis and in microscopic polyangiitis. Arthritis Care Res (Hoboken). 2021;73:1372\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1210_CR96","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40266-020-00782-x","volume":"37","author":"P Mielnik","year":"2020","unstructured":"Mielnik P, et al. Does older age have an impact on rituximab efficacy and safety? Results from the NOR-DMARD register. Drugs Aging. 2020;37:617\u201326.","journal-title":"Drugs Aging"},{"key":"1210_CR97","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/gerona\/gly197","volume":"74","author":"DH Kim","year":"2019","unstructured":"Kim DH, et al. Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study. J Gerontol A Biol Sci Med Sci. 2019;74:1271\u20136.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1210_CR98","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82:742\u201353.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR99","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler A, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77:1440\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR100","first-page":"152","volume":"4","author":"F Aqeel","year":"2024","unstructured":"Aqeel F, Cammarata MJ, Le D, Geetha D. Pneumocystis jirovecii pneumonia prophylaxis in patients with ANCA vasculitis on rituximab maintenance therapy. Glomerular Dis. 2024;4:152\u20138.","journal-title":"Glomerular Dis"},{"key":"1210_CR101","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","volume":"81","author":"RBM Landew\u00e9","year":"2022","unstructured":"Landew\u00e9 RBM, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. 2022;81:1628\u201339.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.834981","volume":"13","author":"PK Marty","year":"2022","unstructured":"Marty PK, et al. Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-cell depleting therapy. Front Immunol. 2022;13: 834981.","journal-title":"Front Immunol"},{"key":"1210_CR103","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/S2665-9913(21)00394-5","volume":"4","author":"I Jyssum","year":"2022","unstructured":"Jyssum I, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 2022;4:e177\u201387.","journal-title":"Lancet Rheumatol"},{"key":"1210_CR104","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1002\/art.34584","volume":"64","author":"R Cartin-Ceba","year":"2012","unstructured":"Cartin-Ceba R, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): ten-year experience at a single center. Arthritis Rheum. 2012;64:3770\u20138.","journal-title":"Arthritis Rheum"},{"key":"1210_CR105","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen EE, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR106","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638\u201347.","journal-title":"Nat Rev Clin Oncol"},{"key":"1210_CR107","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2023;75:2088\u2013102.","journal-title":"Arthritis Rheumatol"},{"key":"1210_CR108","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2015","unstructured":"Robson J, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54:471\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102466","volume":"19","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ahmed AR. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev. 2020;19: 102466.","journal-title":"Autoimmun Rev"},{"key":"1210_CR110","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4049\/jimmunol.105.4.964","volume":"105","author":"CE Buckley III","year":"1970","unstructured":"Buckley CE III, Dorsey FC. The effect of aging on human serum immunoglobulin concentrations1. J Immunol. 1970;105:964\u201372.","journal-title":"J Immunol"},{"key":"1210_CR111","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","volume":"19","author":"J Thiel","year":"2017","unstructured":"Thiel J, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19:101.","journal-title":"Arthritis Res Ther"},{"key":"1210_CR112","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco H, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15:178.","journal-title":"BMC Musculoskelet Disord"},{"key":"1210_CR113","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong M-S, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1: e184169.","journal-title":"JAMA Netw Open"},{"key":"1210_CR114","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/rheumatology\/key394","volume":"58","author":"S Wijetilleka","year":"2019","unstructured":"Wijetilleka S, et al. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Rheumatology (Oxford). 2019;58:889\u201396.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR115","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/jnu.12397","volume":"50","author":"S-F Chang","year":"2018","unstructured":"Chang S-F, Lin H-C, Cheng C-L. The relationship of frailty and hospitalization among older people: evidence from a meta-analysis. J Nurs Scholarsh. 2018;50:383\u201391.","journal-title":"J Nurs Scholarsh"},{"key":"1210_CR116","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1532-5415.2008.02136.x","volume":"57","author":"JA Avila-Funes","year":"2009","unstructured":"Avila-Funes JA, et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc. 2009;57:453\u201361.","journal-title":"J Am Geriatr Soc"},{"key":"1210_CR117","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/gerona\/glr142","volume":"66A","author":"TM Gill","year":"2011","unstructured":"Gill TM, Gahbauer EA, Han L, Allore HG. The relationship between intervening hospitalizations and transitions between frailty states. J Gerontol A. 2011;66A:1238\u201343.","journal-title":"J Gerontol A"},{"key":"1210_CR118","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/j.1532-5415.2005.53405.x","volume":"53","author":"N Fugate Woods","year":"2005","unstructured":"Fugate Woods N, et al. Frailty: emergence and consequences in women aged 65 and older in the women\u2019s health initiative observational study. J Am Geriatrics Soc. 2005;53:1321\u201330.","journal-title":"J Am Geriatrics Soc"},{"key":"1210_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101947","volume":"59","author":"EL Boucher","year":"2023","unstructured":"Boucher EL, Gan JM, Rothwell PM, Shepperd S, Pendlebury ST. Prevalence and outcomes of frailty in unplanned hospital admissions: a systematic review and meta-analysis of hospital-wide and general (internal) medicine cohorts. eClinicalMedicine. 2023;59: 101947.","journal-title":"eClinicalMedicine"},{"key":"1210_CR120","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley AR, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371\u201380.","journal-title":"Arthritis Rheum"},{"key":"1210_CR121","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/rheumatology\/keaa215","volume":"60","author":"S Monti","year":"2021","unstructured":"Monti S, et al. Association between age at disease onset of anti-neutrophil cytoplasmic antibody\u2013associated vasculitis and clinical presentation and short-term outcomes. Rheumatology. 2021;60:617\u201328.","journal-title":"Rheumatology"},{"key":"1210_CR122","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/joim.13417","volume":"291","author":"S Thietart","year":"2022","unstructured":"Thietart S, et al. Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: a multicentre cohort study. J Intern Med. 2022;291:350\u201363.","journal-title":"J Intern Med"},{"key":"1210_CR123","doi-asserted-by":"publisher","first-page":"7581567","DOI":"10.1155\/2018\/7581567","volume":"2018","author":"R Bj\u00f8rneklett","year":"2018","unstructured":"Bj\u00f8rneklett R, Bostad L, Fismen A-S. Prognosis and histological classification in elderly patients with anca-glomerulonephritis: a registry-based cohort study. Biomed Res Int. 2018;2018:7581567.","journal-title":"Biomed Res Int"},{"key":"1210_CR124","first-page":"284","volume":"24","author":"M Andrews","year":"1990","unstructured":"Andrews M, Edmunds M, Campbell A, Walls J, Feehally J. Systemic vasculitis in the 1980s\u2014Is there an increasing incidence of Wegener\u2019s graanulomatosis and microscopic polyarteritis? J R Coll Physicians Lond. 1990;24:284\u20138.","journal-title":"J R Coll Physicians Lond"},{"key":"1210_CR125","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/1529-0131(200011)43:11<2481::AID-ANR15>3.0.CO;2-6","volume":"43","author":"W Koldingsnes","year":"2000","unstructured":"Koldingsnes W, Nossent H. Epidemiology of Wegener\u2019s granulomatosis in northern Norway. Arthritis Rheum. 2000;43:2481\u20137.","journal-title":"Arthritis Rheum"},{"key":"1210_CR126","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/ard.2004.022335","volume":"64","author":"J Dadoniene","year":"2005","unstructured":"Dadoniene J, Kirdaite G, Mackiewicz Z, Rimkevicius A, Haugeberg G. Incidence of primary systemic vasculitides in Vilnius: a university hospital population based study. Ann Rheum Dis. 2005;64:335\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1210_CR127","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4081\/rr.2010.e8","volume":"2","author":"AS Zeft","year":"2010","unstructured":"Zeft AS, et al. Wegener\u2019s granulomatosis and environmental factors in Western Montana. Rheumatol Reports. 2010;2:e8\u2013e8.","journal-title":"Rheumatol Reports"},{"key":"1210_CR128","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1445-5994.2008.01672.x","volume":"38","author":"AS Ormerod","year":"2008","unstructured":"Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J. 2008;38:816\u201323.","journal-title":"Intern Med J"},{"key":"1210_CR129","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.semarthrit.2014.05.005","volume":"44","author":"M Catanoso","year":"2014","unstructured":"Catanoso M, et al. Epidemiology of granulomatosis with polyangiitis (Wegener\u2019s granulomatosis) in Northern Italy: a 15-year population-based study. Semin Arthritis Rheum. 2014;44:202\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"1210_CR130","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/rheumatology\/kep304","volume":"48","author":"AJ Mohammad","year":"2009","unstructured":"Mohammad AJ, Jacobsson LTH, Westman KWA, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener\u2019s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48:1560\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR131","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jmii.2013.12.006","volume":"48","author":"C-S Wu","year":"2015","unstructured":"Wu C-S, Hsieh C-J, Peng Y-S, Chang T-H, Wu Z-Y. Antineutrophil cytoplasmic antibody-associated vasculitis in Taiwan: A hospital-based study with reference to the population-based National Health Insurance database. J Microbiol Immunol Infect. 2015;48:477\u201382.","journal-title":"J Microbiol Immunol Infect"},{"key":"1210_CR132","first-page":"589","volume":"56","author":"FA Pearce","year":"2017","unstructured":"Pearce FA, Grainge MJ, Lanyon PC, Watts RA, Hubbard RB. The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink. Rheumatology (Oxford). 2017;56:589\u201396.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR133","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002949","volume":"9","author":"J Rathmann","year":"2023","unstructured":"Rathmann J, Segelmark M, Englund M, Mohammad AJ. Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study. RMD Open. 2023;9: e002949.","journal-title":"RMD Open"},{"key":"1210_CR134","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/rheumatology\/41.5.540","volume":"41","author":"E Reinhold-Keller","year":"2002","unstructured":"Reinhold-Keller E, et al. No difference in the incidences of vasculitides between north and south Germany: first results of the German vasculitis register. Rheumatology (Oxford). 2002;41:540\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR135","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/rheumatology\/kez597","volume":"59","author":"AT Nilsen","year":"2020","unstructured":"Nilsen AT, et al. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. Rheumatology (Oxford). 2020;59:2316\u201324.","journal-title":"Rheumatology (Oxford)"},{"key":"1210_CR136","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s10067-019-04463-y","volume":"38","author":"FS Pierini","year":"2019","unstructured":"Pierini FS, Scolnik M, Scaglioni V, Mollerach F, Soriano ER. Incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. Clin Rheumatol. 2019;38:1935\u201340.","journal-title":"Clin Rheumatol"},{"key":"1210_CR137","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1445-5994.2008.01694.x","volume":"38","author":"P Hissaria","year":"2008","unstructured":"Hissaria P, et al. Wegener\u2019s granulomatosis: epidemiological and clinical features in a South Australian study. Intern Med J. 2008;38:776\u201380.","journal-title":"Intern Med J"},{"key":"1210_CR138","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10067-016-3232-y","volume":"35","author":"\u00d6N Pamuk","year":"2016","unstructured":"Pamuk \u00d6N, D\u00f6nmez S, Calay\u0131r GB, Pamuk GE. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey. Clin Rheumatol. 2016;35:2063\u201371.","journal-title":"Clin Rheumatol"},{"key":"1210_CR139","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/5584_2018_239","volume-title":"Clinical medicine research","author":"K Kanecki","year":"2018","unstructured":"Kanecki K, et al. Epidemiology of granulomatosis with polyangiitis in Poland, 2011\u20132015. In: Pokorski M, editor., et al., Clinical medicine research, vol. 1116. Cham: Springer International Publishing; 2018. p. 131\u20138."},{"key":"1210_CR140","first-page":"409","volume":"27","author":"SH Panagiotakis","year":"2009","unstructured":"Panagiotakis SH, et al. The epidemiology of primary systemic vasculitides involving small vessels in Crete (southern Greece): a comparison of older versus younger adult patients. Clin Exp Rheumatol. 2009;27:409\u201315.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01210-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:25:56Z","timestamp":1757183156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01210-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":140,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01210-8","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"15 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Trento within the CRUI-CARE Agreement. This study was supported by a research grant from the Vasculitis foundation to Dr. Alvise Berti ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. U. Specks has received research grants from Amgen, AstraZeneca, GSK, Genentech\/Roche, NorthStar Medical Radioisotopes, Novartis, and NS Pharma and consulting and advisory board fees from Amgen, AstraZeneca, Argenx, BoehringerIngelheim, CSL Vifor, and Novartis, all unrelated to the present publication. Dr. A. Berti has served on advisory boards and has received lecturing fees from GSK, all unrelated to the present publication. Dr. D. Cornec, Dr. Giulia Boscato Sopetto, and Dr. Baptiste Chevet have no personal conflicts of interest. Dr. C. Pagnoux has received fees unrelated to the present publication for serving on advisory boards from Chemocentryx, Otsuka, GlaxoSmithKline, AstraZeneca, NeoVii, and Hoffman-LaRoche; for lecture fees from Hoffman-La Roche, GlaxoSmithKline; and educational grant support from Hoffman-La Roche, Otsuka, Pfizer, and GlaxoSmithKline.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data And Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"B.C. and G.B.S. drafted the first version of the manuscript. D.C. and A.B. contributed to the study conception and design and supervised the writing. U.S. and C.P. reviewed the second version of the paper. All authors discussed the results, commented on the manuscript, and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}